Chemistry:Ibodutant
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Other names | 6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4- yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide |
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C37H48N4O4S |
Molar mass | 644.88 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. (As of March 2015), it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.[1]
See also
- GR-159,897
- Nepadutant
- Saredutant
References
Further reading
- "Neue Wirkstoffe - Ibodutant" (in de). Österreichische Apothekerzeitung (11/2008): 541. May 26, 2008.
- "Ibodutant. Tachykinin NK2 receptor antagonist, Treatment of irritable bowel syndrome.". Drugs of the Future 33 (2): 111–115. doi:10.1358/dof.2008.033.02.1181381.
![]() | Original source: https://en.wikipedia.org/wiki/Ibodutant.
Read more |